These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10564693)
1. Thalidomide--a revival story. Raje N; Anderson K N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693 [No Abstract] [Full Text] [Related]
2. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach]. Hattori Y; Kakimoto T Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105 [No Abstract] [Full Text] [Related]
3. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Rajkumar SV; Witzig TE Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136 [TBL] [Abstract][Full Text] [Related]
4. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832 [TBL] [Abstract][Full Text] [Related]
5. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients. Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985 [No Abstract] [Full Text] [Related]
7. Is thalidomide a true anti-angiogenic molecule in multiple myeloma? Ribatti D; Vacca A Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476 [No Abstract] [Full Text] [Related]
8. Thalidomide: present and future in multiple myeloma. Hussein MA Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435 [TBL] [Abstract][Full Text] [Related]
9. [Thalidomide: the revival]. Grosbois B; Duguet C Rev Med Interne; 2001 Jan; 22(1):5-7. PubMed ID: 11218298 [No Abstract] [Full Text] [Related]
10. Antitumor activity of thalidomide in refractory multiple myeloma. Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685 [TBL] [Abstract][Full Text] [Related]
11. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. Wang M; Liu Y; Li Y; Wu H Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346 [TBL] [Abstract][Full Text] [Related]
13. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide]. Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349 [TBL] [Abstract][Full Text] [Related]
14. Thalidomide in the treatment of multiple myeloma. Rajkumar SV Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124 [TBL] [Abstract][Full Text] [Related]
15. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma. Ribatti D; Vacca A Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735 [No Abstract] [Full Text] [Related]
18. Thalidomide--a treatment for cancer? Mayo Clin Health Lett; 2000 Jun; 18(6):4. PubMed ID: 10868128 [No Abstract] [Full Text] [Related]
19. Thalidomide shows promise as cancer treatment. Health News; 2000 Jan; 6(1):8. PubMed ID: 11019665 [No Abstract] [Full Text] [Related]
20. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma]. Li J; Luo SK; Hong WD; Zhou ZH; Zou WY Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]